Literature DB >> 16959941

cAMP inhibits transforming growth factor-beta-stimulated collagen synthesis via inhibition of extracellular signal-regulated kinase 1/2 and Smad signaling in cardiac fibroblasts.

Xiaoqiu Liu1, Shu Qiang Sun, Aviv Hassid, Rennolds S Ostrom.   

Abstract

Cardiac fibroblasts produce and degrade extracellular matrix and are critical in regulating cardiac remodeling and hypertrophy. Cytokines such as transforming growth factor-beta (TGF-beta) play a fundamental role in the development of tissue fibrosis by stimulating matrix deposition and other profibrotic responses, but less is known about pathways that might inhibit fibrosis. Increased cAMP formation inhibits myofibroblast differentiation and collagen production by cardiac fibroblasts, but the mechanism of this inhibition is not known. We sought to characterize the signaling pathways by which cAMP-elevating agents alter collagen expression and myofibroblast differentiation. Treatment with 10 microM forskolin or isoproterenol increased cAMP production and cAMP response element binding protein (CREB) phosphorylation in cardiac fibroblasts and inhibited serum- or TGF-beta-stimulated collagen synthesis by 37% or more. These same cAMP-elevating agents blunted TGF-beta-stimulated expression of collagen I, collagen III, and alpha-smooth muscle actin. Forskolin or isoproterenol treatment blocked the activation of extracellular signal-regulated kinase 1/2 (ERK1/2) induced by TGF-beta despite the fact that these cAMP-elevating agents stimulated ERK1/2 activation on their own. cAMP-elevating agents also attenuated the activation of c-Jun NH(2)-terminal kinase and reduced binding of the transcriptional coactivator CREB-binding protein 1 to transcriptional complexes containing Smad2, Smad3, and Smad4. Pharmacological inhibition of ERK completely blocked TGF-beta-stimulated collagen gene expression, but expression of an active mutant of MEK was additive with TGF-beta treatment. Thus, cAMP-elevating agents inhibit the profibrotic effects of TGF-beta in cardiac fibroblasts largely through inhibiting ERK1/2 phosphorylation but also by reducing Smad-mediated recruitment of transcriptional coactivators.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16959941     DOI: 10.1124/mol.106.028951

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  53 in total

1.  Omega-3 fatty acids prevent pressure overload-induced cardiac fibrosis through activation of cyclic GMP/protein kinase G signaling in cardiac fibroblasts.

Authors:  Jinghai Chen; Gregory C Shearer; Quanhai Chen; Chastity L Healy; April J Beyer; Vijaya B Nareddy; A Martin Gerdes; William S Harris; Timothy D O'Connell; Dajun Wang
Journal:  Circulation       Date:  2011-01-31       Impact factor: 29.690

2.  Adenosine 2A receptor promotes collagen production by human fibroblasts via pathways involving cyclic AMP and AKT but independent of Smad2/3.

Authors:  Miguel Perez-Aso; Patricia Fernandez; Aránzazu Mediero; Edwin S Chan; Bruce N Cronstein
Journal:  FASEB J       Date:  2013-11-07       Impact factor: 5.191

3.  Fibroblast-specific expression of AC6 enhances beta-adrenergic and prostacyclin signaling and blunts bleomycin-induced pulmonary fibrosis.

Authors:  Xiaoqiu Liu; Fengying Li; Shu Qiang Sun; Muthusamy Thangavel; Joseph Kaminsky; Louisa Balazs; Rennolds S Ostrom
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2010-03-26       Impact factor: 5.464

Review 4.  Molecular determinants of mesenchymal cell activation in fibroproliferative diseases.

Authors:  Loka R Penke; Marc Peters-Golden
Journal:  Cell Mol Life Sci       Date:  2019-09-28       Impact factor: 9.261

5.  Reduced collagen deposition in infarcted myocardium facilitates induced pluripotent stem cell engraftment and angiomyogenesis for improvement of left ventricular function.

Authors:  Bo Dai; Wei Huang; Meifeng Xu; Ronald W Millard; Mei Hua Gao; H Kirk Hammond; Donald R Menick; Muhammad Ashraf; Yigang Wang
Journal:  J Am Coll Cardiol       Date:  2011-11-08       Impact factor: 24.094

6.  Pharmacological and Activated Fibroblast Targeting of Gβγ-GRK2 After Myocardial Ischemia Attenuates Heart Failure Progression.

Authors:  Joshua G Travers; Fadia A Kamal; Iñigo Valiente-Alandi; Michelle L Nieman; Michelle A Sargent; John N Lorenz; Jeffery D Molkentin; Burns C Blaxall
Journal:  J Am Coll Cardiol       Date:  2017-08-22       Impact factor: 24.094

7.  Estrogen receptor-beta prevents cardiac fibrosis.

Authors:  Ali Pedram; Mahnaz Razandi; Fiona O'Mahony; Dennis Lubahn; Ellis R Levin
Journal:  Mol Endocrinol       Date:  2010-09-01

Review 8.  Cardiac Fibrosis: The Fibroblast Awakens.

Authors:  Joshua G Travers; Fadia A Kamal; Jeffrey Robbins; Katherine E Yutzey; Burns C Blaxall
Journal:  Circ Res       Date:  2016-03-18       Impact factor: 17.367

9.  Hypoxia reduces TGFbeta1-induced corneal keratocyte myofibroblast transformation.

Authors:  Dongmei Xing; Joseph A Bonanno
Journal:  Mol Vis       Date:  2009-09-11       Impact factor: 2.367

Review 10.  Cellular mechanisms of tissue fibrosis. 8. Current and future drug targets in fibrosis: focus on Rho GTPase-regulated gene transcription.

Authors:  Pei-Suen Tsou; Andrew J Haak; Dinesh Khanna; Richard R Neubig
Journal:  Am J Physiol Cell Physiol       Date:  2014-04-16       Impact factor: 4.249

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.